MARKET

AUPH

AUPH

Aurinia Pharmace
NASDAQ
5.04
+0.04
+0.70%
Opening 11:38 03/28 EDT
OPEN
4.990
PREV CLOSE
5.00
HIGH
5.04
LOW
4.970
VOLUME
354.48K
TURNOVER
0
52 WEEK HIGH
12.43
52 WEEK LOW
4.850
MARKET CAP
728.15M
P/E (TTM)
-9.2436
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at AUPH last week (0318-0322)?
Weekly Report · 3d ago
Aurinia Pharmace: [Amend]General statement of acquisition of beneficial ownership
Press release · 03/20 22:20
Weekly Report: what happened at AUPH last week (0311-0315)?
Weekly Report · 03/18 10:31
Weekly Report: what happened at AUPH last week (0304-0308)?
Weekly Report · 03/11 10:29
Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Aurinia Pharmaceuticals Inc. Had been conducting a strategic review since June 2023. The strategic review did not result in a formal offer to buy the company. AUPH has decided to buy back its own stock and focus on Lupkynis. The company is discontinuing development of two drugs.
Seeking Alpha · 03/05 20:27
Weekly Report: what happened at AUPH last week (0226-0301)?
Weekly Report · 03/04 10:31
Aurinia Pharmaceuticals Price Target Maintained With a $13.00/Share by HC Wainwright & Co.
Dow Jones · 03/01 19:18
Aurinia Pharmaceuticals: Strong Buy Rating Amidst Share Repurchase and Promising LUPKYNIS Prospects
TipRanks · 03/01 16:55
More
About AUPH
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical, and regulatory activities to support the voclosporin development program. LUPKYNIS is a calcineurin inhibitor (CNI) immunosuppressant, that improves near and long-term outcomes in LN when used in combination with mycophenolate mofetil (MMF) and steroids. LUPKYNIS reduces cytokine activation and blocks interleukin IL-2 expression and T-cell mediated immune responses. Voclosporin, the active ingredient in LUPKYNIS, is made by a modification of a single amino acid of the cyclosporine molecule. Its product pipeline includes AUR200 and AUR300.

Webull offers Aurinia Pharmaceuticals Inc stock information, including NASDAQ: AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.